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Adjuvant tamoxifen treatment reduces the occurrence of contralateral breast cancer (CBC). The aim of the study was to investigate
the hypothesis that adjuvant tamoxifen reduces the occurrence of oestrogen-receptor (ER)-positive CBC, but not the growth of ER-
negative CBCs, and to examine survival after diagnosis of CBC. For the study, ER status was immunohistochemically assessed in CBCs
of 35 tamoxifen-treated patients and 115 patients without previous hormonal treatment. Cases were retrieved from a series of
patients treated from 1984 to 1995 at nine hospitals. The interval between ipsi- and contralateral breast cancer was at least 1 year. It
was seen that the proportion of patients with an ER-negative CBC was significantly higher among those with prior tamoxifen
treatment: 37% vs 18% (P¼0.047). No difference between the two groups in overall and disease-specific survival following CBC was
found. However, the stage differed for both groups: tamoxifen users more often had node-positive contralateral disease (P¼ 0.045).
In conclusion, metachronous CBCs developing after 1–3 years of tamoxifen treatment are more often ER-negative breast cancers. So
far this does not seem to have a major impact on survival.
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Tamoxifen as an antioestrogenic drug was introduced in the
seventies and is now widely used as adjuvant and palliative
treatment in breast cancer patients. Tamoxifen use as adjuvant
treatment prevents new breast cancers or delays disease progres-
sion. The drug blocks the binding of oestrogens to the human
oestradiol receptors (ER), which are specific proteins in the human
breast cell. Oestrogens have, by means of the ER, a proliferating
effect on breast cancer cells. The presence of the receptor is a
predictor of the endocrine responsiveness of breast cancer cells to
tamoxifen (De Placido et al, 1990; Early Breast Cancer Trialists’
Collaborative Group (EBCTCG), 1998; Chlebowski et al, 1999;
Radmacher et al, 2000).
In the EBCTCG overview of tamoxifen trials, recurrence
reductions of 21, 28 and 50%, respectively, after 1, 2 and 5 years
of tamoxifen treatment were found in ER-positive breast cancer
patients after about 10 years of follow-up. Moreover, adjuvant
tamoxifen has an effect on the prevention of contralateral breast
cancer (CBC): by the EBCTCG, reductions of 13, 26 and 47%,
respectively, were found after 1, 2 and 5 years of tamoxifen
treatment (Early Breast Cancer Trialists’ Collaborative Group,
1998). These reductions did not depend on dose. Some data
suggest that primarily ER-positive CBCs were reduced. In
contralateral breast tumours, more often a negative ER status
(47% in tamoxifen users vs 12% in nonusers) was observed after
tamoxifen treatment, but the numbers were very small (Rutqvist et
al, 1991). A randomised prevention trial comparing tamoxifen (20
mg daily for 5 years) with placebo in healthy women at high risk
for breast cancer showed a reduction in the incidence of invasive
breast cancer of approximately 50% through 69 months of follow-
up (Fisher et al, 1998). In the tamoxifen arm, the occurrence of ER-
positive tumours was decreased by 69%, but no difference (38 vs 31
breast cancers) was seen in the occurrence of ER-negative
tumours. The ER+/ER  ratio was 1.07 in tamoxifen users vs 4.19
in nonusers. The recent results of the IBIS I trial are consistent
with these results; here also no difference in absolute numbers of
ER-negative tumours was seen (19 vs 19 breast cancers) (IBIS
Investigators, 2002).
It is therefore suggested that the benefit of tamoxifen in breast
cancer treatment and prevention results from the growth
inhibition of occult ER-positive tumours, and that tamoxifen is
unlikely to prevent the progression of ER-poor tumours, which is
said to be associated with a less favourable prognosis (Fisher et al,
1998). In relation to this, and because of other events that influence
morbidity, it has been speculated that the preventive effect of
tamoxifen on breast cancer mortality in healthy women might be
limited.
We examined these issues by comparing the ER status of CBCs
between two groups of postmenopausal patients with bilateral
breast cancer, who had and had not received adjuvant tamoxifen
for their initial breast cancer. In addition, we examined survival in
tamoxifen-treated and nontreated patients after the diagnosis of
CBC.
METHODS
For this study, we identified all postmenopausal patients treated
for a primary operable invasive breast cancer between 1984 and
1995, who were diagnosed with a CBC at least 1 year later. Patients
Received 29 May 2002; revised 31 October 2002; accepted 11
November 2002
*Correspondence: Dr R Kaas; E-mail: reinie@kaas.nl
British Journal of Cancer (2003) 88, 707–710






























yfrom two cohorts were selected from the Netherlands Cancer
Institute/Antoni van Leeuwenhoek Ziekenhuis (NKI/AvL) in
Amsterdam and from the Comprehensive Cancer Centre South
(CCCS), which includes patients from eight community hospitals
in the southeast of the Netherlands. Follow-up closed in December
1999.
In the study period, approximately 2850 operable postmeno-
pausal women (or 51 years of age and older) were treated for a first
primary breast cancer in the NKI/AvL; 1071 received adjuvant
tamoxifen. In the hospitals covered by the CCCS, 2923 post-
menopausal patients (all stages) were treated in this period; 807 of
them received tamoxifen.
At the NKI/AvL, node-positive and node-negative breast cancer
patients were randomised in an adjuvant tamoxifen trial to receive
tamoxifen 30 mg day
 1 for 1 or 3 years. ER status was not an
eligibility criterion. The standard treatment in the CCCS region
was adjuvant tamoxifen at a daily dose of 20mg. Initially, the use
was restricted to patients with ER-positive tumours. In both
cohorts, primary node-positive, ER-positive and ER-negative
patients were increasingly treated with tamoxifen, 20mg day
 1
from 1988 onwards. Treatment for the CBC was only local and no
systemic treatment was administered.
The follow-up scheme as advised by the ASCO was the same for
the ipsi- as for the contralateral tumour (American Society of
Clinical Oncology, 1997).
In total, we identified 150 patients with metachronous CBC: 35
tamoxifen-treated patients and 115 patients without previous
tamoxifen treatment. Excluded were patients with ipsilateral local
recurrence or distant disease at diagnosis of the CBC, because the
differential diagnosis between second primary tumour or meta-
stasis in the breast would be difficult in those patients. Patients
with a contralateral ductal in situ cancer were included in the
analysis, but not patients with lobular in situ carcinoma.
The data of the original ER reports (mostly analysis by
biochemical methods) were used for the primary breast cancers.
The paraffin blocks of the CBCs were requested from the different
hospitals for immunohistochemical receptor analysis. Paraffin
blocks of 30 patients of the treated group and 98 of the nonusers
group were available for receptor analysis (staining with DAKO,
clone 1D5, 1:500). The ER status was considered positive in
cancers with more than 10% nuclear staining.
Medical records were reviewed for clinical data: age, date of
diagnosis, stage and ER status of both ipsi- and contralateral
tumour, interval between ipsi- and contralateral tumor, tamoxifen
treatment with dose and treatment duration and follow-up status
up to December 1999.
Statistical methods
For 2 2 tables P-values were calculated from Fisher’s exact test.
The comparison between ipsi- and contralateral breast cancers was
done by the test of McNemar.
The triple association between tamoxifen treatment and ER
status of first and second tumour was investigated by using binary
repeated measurements analysis. Survival curves were calculated
using the method of Kaplan and Meier and compared by the log-
rank test. For overall survival the event of interest was death from
any cause, and for disease-specific survival death from breast
cancer.
The statistical package SAS 6, 12 – specifically the procedures
TTEST, FREQ, CATMOD, GLM, and LIFETEST – was used for all
analyses.
RESULTS
Among the 150 patients with CBC, 35 (23%) had been treated with
adjuvant tamoxifen; 22 from the NKI and 13 from the CCCS. The
mean age at first breast cancer was 62.477.4 (s.d.) years (range 51
– 77), and the mean age at diagnosis of the CBC was 67.177.4
(s.d.) years (range 54–79). The mean age at first breast cancer and
CBC did not differ between the tamoxifen- and the nontreated
group (see Tables 1 and 2). Of the 5773 patients treated in the two
cohorts in the study period, 1878 (33%) received adjuvant
tamoxifen. For the tamoxifen-treated patients, a crude CBC
frequency of 1.9% was found and for the nonusers, a frequency
of 3.0%.
Since tamoxifen was prescribed to node-positive patients in
particular, the stage of the primary breast tumour differed between
both groups (Table 1). The tumour stage of the second breast
cancer (Table 2) also only slightly differed between the tamoxifen-
treated and the nontreated patients, with proportions of pTis+pT1
tumours of 74 and 82%, respectively, (Fisher’s exact test P¼0.33).
For nodal stage, a difference between the groups was found: the
proportion with pN1 was 42% for the treated and 23% for the
nontreated group (P¼0.045). Overall, relatively more small
tumours were found as compared to the first breast cancer,
(McNemar’s test Po0.0001).
Table 1 Characteristics of first primary breast cancer in CBC – cases with and without previous tamoxifen
treatment
Tamoxifen users Tamoxifen nonusers
Characteristics n=35 23% n=115 77%
Mean age at diagnosis7s.d. 62.477.4year 62.978.6year
Range (51–77) (49–81)
Pathological tumour size
pT1 (1–20mm) 9/35 26% 73/115 63%
pT2 (21–50mm) 20/35 57% 40/115 35%
pT3 (>50mm) 5/35 14% 2/115 2%
Pathological nodal status
pN0 6/35 17% 90/115 78%
ER status
a
Negative 3/29 10% 12/78 15%
Unknown n=6 n=37
Family history: at least
one first degree member
15/33 45% 37/110 34%
BC=breast cancer; ER=oestrogen receptor.
aER status from original test result, mostly biochemical.
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yTamoxifen users appear to have more often ER-negative second
breast cancers than nonusers: 37 vs 18% (P¼0.047). Among the
patients not treated with tamoxifen, the proportions of ER-
negative tumours were quite similar for the first and the
contralateral breast tumour: 15 and 18%. In the tamoxifen-treated
group, however, 10% of the first primary tumours were ER
negative, and 37% of the contralateral tumours (McNemar’s test
P¼0.016). Therefore, a binary repeated measurement analysis was
done, indicating an increase in the proportion of ER-negative
tumours between the first and the CBC in tamoxifen-treated
patients compared to patients without previous tamoxifen treat-
ment (P¼0.012). This analysis was carried out on 88 of the
patients for whom ER status was known for both tumours.
The difference between the tamoxifen users and nonusers
regarding ER negativity of the second breast cancer seems to be
especially large in the late (45 years) CBC group (P¼0.005).
However, this differential effect of interval may still be because of
chance (interval tamoxifen interaction: P¼0.091 in exact logistic
regression).
Figures 1 and 2 show the overall and disease-specific survival
curves from the time of diagnosis of the second breast cancer,
according to tamoxifen use for the first breast cancer. Six-year
overall survival for nontreated patients was 70 vs 69% for
tamoxifen-treated patients (P¼0.45), and disease-specific survival
was 88 vs 78%, respectively (P¼0.14). Adjustment for stage did
not change these results (Figure 3).
DISCUSSION
In this analysis of ER status in CBC patients, we found a greater
proportion of ER-negative second cancers in tamoxifen-treated
patients than in patients without tamoxifen treatment. The stage of
these ER-negative CBCs was more often node positive, but this
result did not seem to have a major impact on survival after the
diagnosis and treatment of contralateral disease. This finding is in
agreement with Rutqvist et al (1991) who reported 47% of ER-
negative CBCs during and after tamoxifen use vs 12% in nonusers.
Table 2 Characteristics of CBCs in patients with and without previous tamoxifen treatment
Tamoxifen users Tamoxifen nonusers
n=35 23% n=115 77% P-value
Mean age at diagnosis7s.d. 67.177.4 year 67.178.9 year
Range (54 – 79) (51 – 88)
Interval IBC – CBC
o2 years 7/35 20% 19/115 17%
2–5 years 12/35 34% 44/115 38%
>5 years 16/35 46% 52/115 45%
Pathol. tumour size
pTis 5/34 15% 7/112 6%
pT1 (1–20mm) 20/34 59% 85/112 78% 0.33
a
pT2 (21–50mm) 5/34 15% 17/112 16%
pT3 (>50mm) 4/34 12% 3/112 3%
Pathol. nodal status
pN0 19/33 58% 87/113 77% 0.045
pN1 14/33 42% 26/113 23%
ER status
b
Negative 11/30 37% 18/98 18% 0.047
Positive 19/30 63% 80/98 82%
Unknown n=5 n=17
IBC=ipsilateral breast cancer; CBC=contralateral breast cancer; ER=oestrogen receptor;
apTis+pT1 vs pT2+pT3.
bImmunohistochemical test on paraffin blocks: ER negative p10% of cells containing nuclear
staining.
Figure 1 Overall survival curve. Figure 2 Disease-specific survival curve.
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yIn the recent report of Li et al (2001) also an increase was found in
ER-negative CBCs after tamoxifen use: 26 vs 4% in nonusers.
Rutqvist et al (1991) did not find differences in tumour size or
nodal status in the CBCs of tamoxifen-treated and non treated
patients. In the present study, the proportion of early-stage CBC
(stage 0+1) was slightly, but not significantly (P¼0.33), lower in
the tamoxifen-treated group (74%) compared to the nontreated
group (82%); if a difference at all, sensitivity of mammography
(NKI/AvL data not shown) cannot explain this, because sensitivity
was 87% in both groups.
BRCA 1 gene mutation carriers have been reported to develop
ER-negative tumours more often (Loman et al, 1998). In the
present study, no identified carriers were present among the
tamoxifen users. Only one of three ER-negative patients of
the tamoxifen-users group had a weak positive family history. In
the nonusers group, two patients were known BRCA 1 mutation
carriers; both had negative ER of first and second breast cancer.
Thus the greater proportion of second ER-negative breast cancers
cannot be explained by a difference in family history.
Radmacher et al (2000) found more ER-negative tumours in the
second and third year of the tamoxifen treatment. And Rutqvist
et al (1991) found slightly more ER-negative tumours during
tamoxifen treatment or within 3 months after cessation. In the
present study, a significant time dependency for ER-negative
tumours was not established, but a trend for more ER-negative
CBCs was seen 5 years or more since the start of the tamoxifen
treatment. This is somewhat paradoxical, assuming that ER-
positive tumours, occult at diagnosis of the first breast cancer, are
treated by tamoxifen, whereas the ER-negative tumours can grow.
In the first 5 years after diagnosis of the first breast cancer, in both
treatment groups 21% of ER-negative tumours is seen. But after
these 5 years, a difference becomes apparent: of the CBCs in the
nonusers, only 10% has a negative ER, whereas 44% of the CBCs in
tamoxifen users has a negative ER. This could mean that tamoxifen
not only cures but also prevents ER-positive CBCs. This apparent
selection of ER-negative breast cancer after tamoxifen use is more
surprising as Tarone et al (2002) established that the increase in
the incidence of breast cancer after 50 years of age is largely
because of an increase in ER-positive breast cancers, while the
incidence of ER-negative cancers remains constant.
No literature could be found with regard to molecular –
biological mechanisms of second primary breast cancers after
adjuvant tamoxifen treatment. A review of O’Regan and Jordan
(2002) describes the known mechanisms of selective estrogen
receptor modulators (SERMs) at a target site, but the proportions
of ER coregulator proteins and the pathways have not yet been
established. The SERM – ER complex can recruit coactivators and
corepressors, and these complexes may modulate genes by
different pathways.
In the present analysis, 6-year overall survival after diagnosis of
CBC was not different in tamoxifen users and nonusers. A
difference in disease-specific survival at 6 years, 88% in nonusers
vs 78% in tamoxifen users, did not reach statistical significance.
Nor was the 6-year overall survival different for both groups after
adjustment for the stage of the first tumour. A limitation of these
analyses is, however, that the treated and nontreated groups were
not totally comparable regarding other tumour characteristics.
In conclusion, the presented results suggest that the CBCs
developing after 1–3 years of use of adjuvant tamoxifen are more
frequently ER negative, and node positive. This observation,
however, does not seem to have a major impact on the overall
survival.
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